Literature DB >> 16717197

Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza.

Jutta Veits1, Dorothee Wiesner, Walter Fuchs, Bernd Hoffmann, Harald Granzow, Elke Starick, Egbert Mundt, Horst Schirrmeier, Teshome Mebatsion, Thomas C Mettenleiter, Angela Römer-Oberdörfer.   

Abstract

Newcastle disease virus (NDV)-expressing avian influenza virus (AIV) hemagglutinin (HA) of subtype H5 was constructed by reverse genetics. A cloned full-length copy of the genome of the lentogenic NDV strain Clone 30 was used for insertion of the ORF encoding the HA of the highly pathogenic AIV isolate A/chicken/Italy/8/98 (H5N2) in the intergenic region between the NDV fusion and hemagglutinin-neuraminidase (HN) genes. Remarkably, two species of HA transcripts were detected in cells infected with the resultant NDVH5. In a second recombinant (NDVH5m), a NDV transcription termination signal-like sequence located within the HA ORF was eliminated by silent mutations. Consequently, NDVH5m produced 2.7-fold more full-length HA transcripts, expressed higher levels of HA, and also incorporated more HA protein into its envelope than NDVH5. NDVH5m stably expressed the modified HA gene for 10 egg passages and both recombinants were found innocuous after intracerebral inoculation of 1-day-old chickens. Immunization of chickens with NDVH5m induced NDV- and AIVH5-specific antibodies and protected chickens against clinical disease after challenge with a lethal dose of velogenic NDV or highly pathogenic AIV, respectively. Remarkably, shedding of influenza virus was not observed. Furthermore, immunization with NDVH5m permitted serological discrimination of vaccinated and AIV field virus-infected animals based on antibodies against the nucleoprotein of AIV. Therefore, recombinant NDVH5m is suitable as a bivalent vaccine against NDV and AIV and may be used as marker vaccine for the control of avian influenza.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16717197      PMCID: PMC1472452          DOI: 10.1073/pnas.0602461103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses.

Authors:  E Kretzschmar; L Buonocore; M J Schnell; J K Rose
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Vaccines for List A poultry diseases: emphasis on avian influenza.

Authors:  D E Swayne
Journal:  Dev Biol (Basel)       Date:  2003

Review 3.  Reverse genetics of mononegavirales.

Authors:  K K Conzelmann
Journal:  Curr Top Microbiol Immunol       Date:  2004       Impact factor: 4.291

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Generation of recombinant lentogenic Newcastle disease virus from cDNA.

Authors:  Angela Römer-Oberdörfer; Egbert Mundt; Teshome Mebatsion; Ursula J Buchholz; Thomas C Mettenleiter
Journal:  J Gen Virol       Date:  1999-11       Impact factor: 3.891

6.  The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA.

Authors:  P Calain; L Roux
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  DNA sequence and transcriptional analysis of the UL1 to UL5 gene cluster of infectious laryngotracheitis virus.

Authors:  W Fuchs; T C Mettenleiter
Journal:  J Gen Virol       Date:  1996-09       Impact factor: 3.891

8.  Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes.

Authors:  Erica Spackman; Dennis A Senne; T J Myers; Leslie L Bulaga; Lindsey P Garber; Michael L Perdue; Kenton Lohman; Luke T Daum; David L Suarez
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

9.  Recombinant paramyxovirus type 1-avian influenza-H7 virus as a vaccine for protection of chickens against influenza and Newcastle disease.

Authors:  D E Swayne; D L Suarez; S Schultz-Cherry; T M Tumpey; D J King; T Nakaya; P Palese; A Garcia-Sastre
Journal:  Avian Dis       Date:  2003       Impact factor: 1.577

10.  Deletion of the non-essential UL0 gene of infectious laryngotracheitis (ILT) virus leads to attenuation in chickens, and UL0 mutants expressing influenza virus haemagglutinin (H7) protect against ILT and fowl plague.

Authors:  Jutta Veits; Dörte Lüschow; Katharina Kindermann; Ortrud Werner; Jens P Teifke; Thomas C Mettenleiter; Walter Fuchs
Journal:  J Gen Virol       Date:  2003-12       Impact factor: 3.891

View more
  58 in total

1.  Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats.

Authors:  Jinying Ge; Xijun Wang; Lihong Tao; Zhiyuan Wen; Na Feng; Songtao Yang; Xianzhu Xia; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

3.  Avian influenza virus hemagglutinins H2, H4, H8, and H14 support a highly pathogenic phenotype.

Authors:  Jutta Veits; Siegfried Weber; Olga Stech; Angele Breithaupt; Marcus Gräber; Sandra Gohrbandt; Jessica Bogs; Jana Hundt; Jens P Teifke; Thomas C Mettenleiter; Jürgen Stech
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 4.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

5.  Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector.

Authors:  Haroldo Toro; De-chu C Tang; David L Suarez; Matt J Sylte; Jennifer Pfeiffer; Kent R Van Kampen
Journal:  Vaccine       Date:  2006-09-25       Impact factor: 3.641

6.  Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge.

Authors:  S Mark Tompkins; Yuan Lin; George P Leser; Kari A Kramer; Debra L Haas; Elizabeth W Howerth; Jie Xu; Mary J Kennett; Russell K Durbin; Joan E Durbin; Ralph Tripp; Robert A Lamb; Biao He
Journal:  Virology       Date:  2007-01-23       Impact factor: 3.616

Review 7.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

Review 8.  Current status of veterinary vaccines.

Authors:  Els N T Meeusen; John Walker; Andrew Peters; Paul-Pierre Pastoret; Gregers Jungersen
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

9.  What are the risks--hypothetical and observed--of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses?

Authors:  Peter L Collins; Alexander Bukreyev; Brian R Murphy
Journal:  J Virol       Date:  2008-10       Impact factor: 5.103

10.  Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

Authors:  Joshua M DiNapoli; Lijuan Yang; Amorsolo Suguitan; Subbiah Elankumaran; David W Dorward; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.